About
Company Overview
History
Management
Board of Directors
Audit Committee
Corporate Responsibility
Social Responsibility
Sustainable Environment
Corporate Philanthropy
Codes of Ethics
Pipeline
Overview
Pain Management
TLC599
TLC590
Ophthalmology
TLC399
Oncology
TLC178
Infectious Diseases
Ampholipad™
ISPM19
Technology
Sustained Release
BioSeizer
®
Targeted Delivery
NanoX
®
Antibody-Linked Nanomedicines
Other Technologies
Polymeric Micelle
Investors
Overview
Corporate Information
Company Proflie
Corporate Governance
Governance Documents
Management
Board of Directors
News & Events
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Financials
SEC Filings
Financial Statements
Analyst Coverage
Shareholder Resources
Investor FAQs
E-mail Alert
IR Contacts
Shareholders Meeting
Annual Reports
Pressroom
Press Releases
Media Library
Publications
Careers
Benefits
Job Opportunities
Contact Us
Language
English
繁體中文
日本語
Home
Pipeline
Pipeline
Ophthalmology
TLC399
Macular edema
Phase II
About
Company Overview
History
Management
Board of Directors
Audit Committee
Corporate Responsibility
Pipeline
Overview
Pain Management
Ophthalmology
Oncology
Infectious Diseases
Technology
Sustained Release
Targeted Delivery
Other Technologies
Investors
Overview
Corporate Information
News & Events
Stock Information
Financials
Shareholder Resources
Pressroom
Press Releases
Media Library
Publications
Careers
Benefits
Job Opportunities
Contact Us
E-mail Alerts
